NCT06937203
- Objective
- Not yet disclosed
- Design
- Not yet disclosed
- Participants
- Not yet disclosed
- Primary endpoint
- Not yet disclosed
- Results
- Results not yet reported
pharma · Hepatitis B · Mixed Dyslipidemia · ARWR
Arrowhead Pharmaceuticals Ireland
Arrowhead Pharmaceuticals Ireland Limited
Arrowhead Pharmaceuticals is a pharma organization headquartered in Pasadena, USA. It trades on NYSE under ticker ARWR. Primary therapeutic focus areas include Hepatitis B, Mixed Dyslipidemia, Severe Hypertriglyceridemia
177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US HQ
746 Employees
Public company Type
ARWR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US
- Employees
- 746
- Programs
- 63
- Drugs
- 34
- Patents
- 126
ARO-ALK7
Phase 2 · small molecule · Obesity
ARO-ALK7 is a small-molecule therapeutic candidate developed by Arrowhead Pharmaceuticals Ireland Limited for the treatment of obesity. The program is currently in Phase 2 clinical development with an active status as of the latest disclosed milestone on 13 April 2026. The compound represents Arrowhead's entry into the
Internal code AROALK7-1001
At a glance
- Sponsor
- Arrowhead Pharmaceuticals Ireland Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Obesity
- Status
- active
- Trials
- 1
Executive summary
ARO-ALK7 is a small-molecule therapeutic candidate developed by Arrowhead Pharmaceuticals Ireland Limited for the treatment of obesity. The program is currently in Phase 2 clinical development with an active status as of the latest disclosed milestone on 13 April 2026. The compound represents Arrowhead's entry into the obesity therapeutic space, a market segment experiencing significant clinical and commercial interest. The mechanism of action and specific molecular target have not yet been disclosed. ARO-ALK7 is being evaluated in clinical trials registered under NCT06937203. No regulatory approvals have been announced to date, and the program remains in active development with ongoing clinical evaluation. The obesity indication represents a substantial unmet medical need, with multiple therapeutic approaches currently in development and approved use across various mechanisms. Arrowhead's development strategy for ARO-ALK7 positions the company within a competitive landscape that includes both established approved therapies and emerging candidates targeting metabolic disease.
Why this program matters
Obesity represents a significant global health burden with substantial unmet medical need despite the emergence of GLP-1 receptor agonists and other pharmacological interventions. The obesity therapeutics market has experienced rapid expansion driven by efficacy demonstrations and growing clinical adoption. ARO-ALK7's development by Arrowhead Pharmaceuticals reflects the continued investment in obesity treatment options, suggesting potential differentiation through novel mechanism or improved tolerability profile compared to existing therapies. The Phase 2 status indicates the program has progressed beyond initial safety and tolerability assessment, with ongoing evaluation of clinical efficacy. The competitive landscape includes both established agents such as approved small-molecule therapies and emerging candidates, indicating sustained market demand and opportunity. Patient population for obesity therapeutics continues to expand as diagnostic criteria and treatment guidelines evolve globally. Commercial significance is substantial given the prevalence of obesity and the demonstrated market adoption of approved therapies. ARO-ALK7's positioning within Arrowhead's portfolio suggests strategic importance to the company's growth trajectory in metabolic disease. The program's continued active status through 2026 indicates sustained development momentum and commitment to advancing the candidate through clinical evaluation phases.
Drug intelligence
Drug Class: Small-molecule therapeutic candidate
Modality: Small molecule
Indication: Obesity
Mechanism of Action: Not yet disclosed
Molecular Target: Not yet disclosed
Route of Administration: Not yet disclosed
Development Status: Phase 2, active
Sponsor: Arrowhead Pharmaceuticals Ireland Limited
Related Therapies: The obesity therapeutic space includes approved small-molecule agents, GLP-1 receptor agonists, and other metabolic modulators currently in clinical development.
First Approval: Not applicable; ARO-ALK7 has not received regulatory approval
Patent Status: Not yet disclosed
obesity disorder
Also known as: obesity, obesity disease
Overview
A disorder involving an excessive amount of body fat.
Treatment landscape
ClinicalTrials.gov lists 50 registered studies for Obesity (Disorder) (AACT aggregate).
Phase breakdown: NA (46), PHASE4 (3), PHASE3 (1)
Common investigational therapies:
- Tirzepatide
- Placebo
- Semaglutide Pen Injector
- Semaglutide
- Gradual dose reduction of semaglutide
- Abrupt cessation of semaglutide
- GLP-1 Receptor Agonists
- GLP-1 Therapy
- Semaglutide (SEMA)
- Metoclopramide
Disease data sourced from MONDO Disease Ontology (MONDO:0011122), Orphanet — obesity disorder, NCT03412149, NCT06787001, NCT06852391, NCT06881485, NCT06911918, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Clinical development timeline
- Phase 22026-04-13
Latest milestone
ARO-ALK7 remains in active Phase 2 development as of 13 April 2026.
Competitive landscape
The obesity therapeutics landscape includes multiple approved small-molecule agents and emerging candidates. Approved therapies listed in the competitive set include Mysimba (naltrexone/bupropion combination), Mounjaro (tirzepatide, indicated for obesity), and various other metabolic agents. The competitive environment reflects diverse mechanisms including combination therapies, GLP-1 receptor agonists, and other metabolic modulators. ARO-ALK7's specific mechanism of action has not been disclosed, limiting direct mechanistic comparison to identified competitors. The presence of multiple approved therapies and ongoing development programs indicates a robust market opportunity and sustained clinical interest in obesity treatment options. Competitive positioning for ARO-ALK7 will depend on demonstration of efficacy, safety, tolerability, and potential differentiation relative to established and emerging therapies during ongoing clinical evaluation.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Simvastatin | Hospital Authority, Hong Kong | small_molecule | approved |
| Pioglitazone | Takeda | small_molecule | approved |
| Semaglutide B 3.0 mg/ml PDS290 | Disc Medicine | small_molecule | approved |
| Mounjaro solution for injection in pre-filled... for Obesity | The George Institute | small_molecule | approved |
| ESOMEPRAZOLE, ESOMEPRAZOLE | Fondazione Telethon ETS | small_molecule | approved |
| Candesartan and Hydrochlorothiazide | Takeda | small_molecule | approved |
| NN9838-4968 | NovoThirteen | small_molecule | approved |
| Intravenous Ibuprofen | CUMBERLAND PHARMACEUTICALS INC | small_molecule | approved |
| NN9536-7752 | NovoThirteen | small_molecule | approved |
| ANGELO | The George Institute | small_molecule | approved |
| Mysimba 8 mg/90 mg prolonged-release tablets | Disc Medicine | small_molecule | approved |
| RIMEGEPANT , Capsaicin | Disc Medicine | small_molecule | approved |
| SIBUTRAMINE | — | Monoamine transporter inhibitor | Approved |
| SETMELANOTIDE ACETATE | — | Melanocortin receptor 4 agonist | Approved |
| SETMELANOTIDE | — | Melanocortin receptor 4 agonist | Approved |
| RIMONABANT | — | Cannabinoid CB1 receptor antagonist | Approved |
| PHENTERMINE HYDROCHLORIDE | — | Norepinephrine transporter releasing agent | Approved |
| PHENTERMINE | — | Norepinephrine transporter releasing agent | Approved |
| PHENDIMETRAZINE TARTRATE | — | Norepinephrine transporter inhibitor | Approved |
| ORLISTAT | — | Pancreatic lipase inhibitor | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Regulatory intelligence
FDA Status: Not yet disclosed
EMA Status: Not yet disclosed
PMDA (Japan) Status: Not yet disclosed
NMPA (China) Status: Not yet disclosed
ARO-ALK7 has not received regulatory approval in any jurisdiction. The program is in active Phase 2 clinical development. No regulatory filings, breakthrough designations, or other regulatory milestones have been disclosed. Regulatory pathway and timelines for potential future submissions remain undisclosed.
Clinical evidence summary
Key questions answered
What is ARO-ALK7 used for?
ARO-ALK7 is a small-molecule therapeutic candidate in development for the treatment of obesity.
Who is developing ARO-ALK7?
ARO-ALK7 is being developed by Arrowhead Pharmaceuticals Ireland Limited.
What is the current development stage of ARO-ALK7?
ARO-ALK7 is currently in Phase 2 clinical development with active status as of April 2026.
Has ARO-ALK7 been approved by the FDA?
No, ARO-ALK7 has not received FDA approval or any regulatory approval to date.
What is the mechanism of action of ARO-ALK7?
The mechanism of action of ARO-ALK7 has not yet been disclosed by the sponsor.
What is the molecular target of ARO-ALK7?
The specific molecular target of ARO-ALK7 has not yet been disclosed.
What type of drug is ARO-ALK7?
ARO-ALK7 is a small-molecule therapeutic candidate.
What clinical trial is evaluating ARO-ALK7?
ARO-ALK7 is being evaluated in clinical trial NCT06937203, with specific trial details not yet disclosed.
Does ARO-ALK7 have any development partners?
No development partners have been disclosed for ARO-ALK7; it is being developed by Arrowhead Pharmaceuticals Ireland Limited.
What is the route of administration for ARO-ALK7?
The route of administration for ARO-ALK7 has not yet been disclosed.
When was ARO-ALK7 first disclosed?
The first disclosure date for ARO-ALK7 has not been disclosed; the latest milestone update is from April 2026.
What is the expected peak sales potential for ARO-ALK7?
Peak sales projections for ARO-ALK7 have not been disclosed.
How does ARO-ALK7 compare to approved obesity therapies?
Direct comparison is not possible until ARO-ALK7's mechanism of action is disclosed; the obesity market includes approved small-molecule agents and GLP-1 receptor agonists.
What is the competitive landscape for obesity therapeutics?
The obesity therapeutics market includes multiple approved therapies and development-stage candidates with various mechanisms, reflecting sustained clinical and commercial interest.
What are the next expected milestones for ARO-ALK7?
The next expected milestone for ARO-ALK7 has not been disclosed; Phase 2 data readouts and regulatory interactions are potential future catalysts.
Is ARO-ALK7 eligible for any regulatory expedited pathways?
Regulatory pathway designations or expedited development status for ARO-ALK7 have not been disclosed.
Entity relationship graph
ARO-ALK7 → Drug → Target → Indication → Company → Trials → Competitors
Indication
Trials
Competitors
- Simvastatin
- Pioglitazone
- Semaglutide B 3.0 mg/ml PDS290
- Mounjaro solution for injection in pre-filled... for Obesity
- ESOMEPRAZOLE, ESOMEPRAZOLE
- Candesartan and Hydrochlorothiazide
- NN9838-4968
- Intravenous Ibuprofen
- NN9536-7752
- ANGELO
- Mysimba 8 mg/90 mg prolonged-release tablets
- RIMEGEPANT , Capsaicin
- SETMELANOTIDE ACETATE
- SETMELANOTIDE
- RIMONABANT
- PHENTERMINE HYDROCHLORIDE
- PHENTERMINE
- PHENDIMETRAZINE TARTRATE
- ORLISTAT
Analyst insights
Development Status: ARO-ALK7 remains in Phase 2 development with active status maintained through April 2026, indicating sustained clinical evaluation and development momentum.
Strategic Positioning: Arrowhead Pharmaceuticals' investment in obesity therapeutics reflects market opportunity and company strategy to expand presence in metabolic disease. The small-molecule modality suggests potential differentiation from GLP-1 receptor agonist approaches dominating recent obesity therapeutic advances.
Competitive Implications: The obesity market continues to attract development investment despite recent approvals. ARO-ALK7's progression will depend on demonstration of clinical efficacy and safety advantages relative to approved therapies and other development-stage candidates.
Future Catalysts: Expected milestones include Phase 2 data readouts, potential regulatory interactions, and advancement decisions regarding Phase 3 development. Timeline for next disclosed milestone remains undisclosed.
Mechanism Disclosure: Publication or disclosure of ARO-ALK7's mechanism of action and molecular target will be critical for competitive positioning assessment and clinical differentiation evaluation.
Quick answers
Concise, citable answers optimized for AI answer engines.
- What is ARO-ALK7?
- Small-molecule obesity therapeutic in Phase 2 development by Arrowhead Pharmaceuticals Ireland Limited.
- What indication?
- Obesity.
- Current phase?
- Phase 2, active as of April 2026.
- Sponsor company?
- Arrowhead Pharmaceuticals Ireland Limited.
- Modality?
- Small molecule.
- Mechanism of action?
- Not yet disclosed.
- Molecular target?
- Not yet disclosed.
- Route of administration?
- Not yet disclosed.
- FDA approved?
- No, not approved in any jurisdiction.
- Development partner?
- No partner disclosed; developed by Arrowhead alone.
- Clinical trial identifier?
- NCT06937203.
- Latest milestone date?
- 13 April 2026.
- Peak sales projection?
- Not disclosed.
- Regulatory status?
- In development; no approvals or designations disclosed.
- Key competitors?
- Approved obesity therapies include Mysimba, Mounjaro, and other small-molecule agents.
- Patent status?
- Not disclosed.
- First disclosure date?
- Not disclosed.
- Next expected milestone?
- Not disclosed; Phase 2 data readouts anticipated.
- License type?
- Not applicable; internal development program.
- Lead investigator?
- Not disclosed.
- Consensus analyst position?
- Not disclosed.
- Related therapies?
- GLP-1 agonists, combination small-molecule agents, metabolic modulators.
Evidence & sources
- ClinicalTrials.gov NCT06937203 (clinicaltrials)
- Source: phase (source_attribution)
- MONDO Disease Ontology (MONDO:0011122) (mondo)
- Orphanet — obesity disorder (orphanet)
- NCT03412149 (clinicaltrials_gov)
- NCT06787001 (clinicaltrials_gov)
- NCT06852391 (clinicaltrials_gov)
- NCT06881485 (clinicaltrials_gov)
- NCT06911918 (clinicaltrials_gov)
- AACT (ClinicalTrials.gov aggregate) (aact)
- ClinicalTrials.gov (clinicaltrials_gov)
- Open Targets Platform (opentargets)
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.